PuSH - Publication Server of Helmholtz Zentrum München: Phage idiotype vaccination: First phase I/II clinical trial in patients with multiple myeloma.

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... Journal

... Publication Type

... Research Data

... Publication Year

Publication overview

Support & Contact

Contact persons

Help

Data protection

Roehnisch, T.* ; Then, C.* ; Nagel, W. ; Blumenthal, C.* ; Braciak, T.* ; Donzeau, M.* ; Boehm, T.* ; Flaig, M.* ; Bourquin, C.* ; Oduncu, F.*

Phage idiotype vaccination: First phase I/II clinical trial in patients with multiple myeloma.

J. Transl. Med. 12:119 (2014)

Publ. Version/Full Text Volltext

DOI

	Open Access Gold

Abstract
Metrics
Extra information

Background: Multiple myeloma is characterized by clonal expansion of B cells producing monoclonal immunoglobulins or fragments thereof, which can be detected in the serum and/or urine and are ideal target antigens for patient-specific immunotherapies. Methods: Using phage particles as immunological carriers, we employed a novel chemically linked idiotype vaccine in a clinical phase I/II trial including 15 patients with advanced multiple myeloma. Vaccines composed of purified paraproteins linked to phage were manufactured successfully for each patient. Patients received six intradermal immunizations with phage idiotype vaccines in three different dose groups. Results: Phage idiotype was well tolerated by all study participants. A subset of patients (80% in the middle dose group) displayed a clinical response indicated by decrease or stabilization of paraprotein levels. Patients exhibiting a clinical response to phage vaccines also raised idiotype-specific immunoglobulins. Induction of a cellular immune response was demonstrated by a cytotoxicity assay and delayed type hypersensitivity tests. Conclusion: We present a simple, time-and cost-efficient phage idiotype vaccination strategy, which represents a safe and feasible patient-specific therapy for patients with advanced multiple myeloma and produced promising anti-tumor activity in a subset of patients.

Altmetric

Additional Metrics?

[➜Log in]

Edit extra informations Login

Publication type Article: Journal article

Document type Scientific Article

Corresponding Author

Keywords Patient-specific Immunotherapy ; Phage Idiotype Vaccination ; Multiple Myeloma ; Phase I/ii Clinical Trial ; Paraprotein; B-cell Lymphoma; Humoral Immune-response; Pulsed Dendritic Cells; Fc-receptor Genotype; Hla Class-i; Follicular Lymphoma; Antibody-responses; Filamentous Phage; T-cells; Peptide

ISSN (print) / ISBN 1479-5876

e-ISSN 1479-5876

Journal Journal of Translational Medicine

Quellenangaben Volume: 12, Issue: 1, Article Number: 119

Publisher BioMed Central

Publishing Place London

Non-patent literature Publications

Reviewing status Peer reviewed